Swiss Government To Save CHF250 Million With Generic Drug Promotion

(MENAFN- Swissinfo) The government has adopted the revisions to the Ordinance on Health Insurance, the Ordinance on Health Care Services and the Ordinance on Medicinal Products, which will come into force on January 1, 2024.

The focus is on the sale of generic drugs and biosimilar medicines. These equally effective and less expensive drugs are used less often in Switzerland than abroad

Increasing the price gap to the original

The Swiss government is now intervening in the pricing of certain generic drugs and biosimilar medicines with chemical active ingredients because they are about twice as expensive as abroad. The House of Representatives rejected the introduction of a reference price system in 2020 and instructed the government to make adjustments at the ordinance level and enable savings.

Now, for generic drugs of active substances with a market volume of CHF4 million to CHF8 million, the price gap to the original preparation will be increased from 30% to 40%. The price gaps applied in the triennial review will be increased by 5%.



Switzerland remains high price island for drugs

This content was published on May 27, 2021 May 27, 2021 The price of medical drugs in Switzerland remains higher than in other major European markets, especially for generic drugs.

When reviewing generic drugs for which there is no longer an original preparation with the same active ingredient in the list of specialities, a therapeutic cross-comparison with other generic drugs will be carried out to assess cost-effectiveness. At the moment, these generic drugs cannot be reviewed.

The Swiss government is also acting on biosimilar medicines. Up to now, these medicines have been included in the list of specialities if they are at least 25% cheaper than the original biological preparation. In the context of the triennial review, they must be 10% cheaper.


This content was published on Feb 26, 2019 Feb 26, 2019 Insurance companies in Switzerland offer policies for everything from mandatory health coverage to vehicles and personal liability protection.

The assessment of the economic viability of biosimilar medicines is now also carried out both for inclusion in the list of specialities and for the periodic review in the same way as for generic drugs, taking into account market-volume-dependent levels with price gaps of between 20% and 70% to the reference preparations.

Increased deductible

From the beginning of 2024, the deductible rate for patients who purchase expensive original preparations will also be increased. In principle, the deductible amounts to 10% of the costs exceeding the deductible rate. However, medicines will be subject to a deductible of 20% instead of 10% if they are too expensive compared to medicines with the same active ingredient.



Healthcare costs: is the system broken?

This content was published on Sep 7, 2023 Sep 7, 2023 We want to know your thoughts on the matter. Read a selection of articles on the issue and join the discussion on our platform "dialogue".

This increased deductible is now set at 40% with the revision of the ordinance. The rules on the differentiated deductible now also apply to biosimilar medicines. If there are medical reasons why a generic drug should not be dispensed, a more expensive original preparation can still be obtained without an increased deductible. However, this must now be proved with concrete facts.

According to the Swiss government, all these measures should lead to a cost reduction of around CHF250 million per year. The savings potential is "considerable".



Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.